Skip to main
VIGL
VIGL logo

Vigil Neuroscience (VIGL) Stock Forecast & Price Target

Vigil Neuroscience (VIGL) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 13%
Hold 38%
Sell 13%
Strong Sell 0%

Bulls say

Vigil Neuroscience Inc. is benefiting from a potential accelerated approval pathway that hinges on demonstrating a significant reduction in neurodegeneration metrics, such as NfL and changes in ventricular or gray matter volume. The promising results from VG-3927, which showed a dose-dependent reduction in sTREM2 and boasts a favorable safety profile, position the company well for finding a commercial partner to further develop this asset. Additionally, with a current negative enterprise value of $25 million, there appears to be considerable upside potential for Vigil Neuroscience's stock, especially if forthcoming clinical data support the efficacy of its therapeutics.

Bears say

Vigil Neuroscience Inc has experienced significant pressure on its stock, with a decline of 26% following the ALEC TREM2 data readout, indicating investor concerns about the company's performance and future prospects. The company reported a substantial net loss of $23.8 million in its fourth quarter, resulting in a GAAP EPS of $(0.57), which was worse than analyst expectations, further highlighting potential operational challenges. Additionally, the increase in the discount rate to 35% has necessitated a downward revision of the valuation target, now set at $13, which underscores a fundamental negative outlook based on current financial metrics and the risk of commercial execution failure.

Vigil Neuroscience (VIGL) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 13% recommend Buy, 38% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vigil Neuroscience and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vigil Neuroscience (VIGL) Forecast

Analysts have given Vigil Neuroscience (VIGL) a Buy based on their latest research and market trends.

According to 8 analysts, Vigil Neuroscience (VIGL) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vigil Neuroscience (VIGL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.